ERBB2 and neoplasm: One possible explanation for the higher HER2-positivity rate observed in biopsy specimens compared with surgical specimens could be the different cutoff used to define HER2-positivity by IHC (a cluster of five or more tumor cells for biopsies compared with ≥10 % of tumor cells for surgical specimens).